The variable sensitivities of these breast cancer cell lines to navitoclax or S63845 are consistent with other studies showing a lack of correlation between breast cancer subtype and BCL-2/MCL-1 dependencies; instead sensitivity to these drugs are better correlated with the expression profile of BCL-2 family proteins specific to each cell line [39, 42]. This evidence concerns the gene BCL2 and breast cancer.